| Literature DB >> 21191145 |
Simon P Mooijaart1, Diana van Heemst, Raymond Noordam, Maarten P Rozing, Carolien A Wijsman, Anton J M de Craen, Rudi G J Westendorp, Marian Beekman, P Eline Slagboom.
Abstract
Human longevity is in part genetically determined, and the insulin/IGF-1 signal transduction (IIS) pathway has consistently been implicated. In humans, type 2 diabetes is a frequent disease that results from loss of glucose homeostasis and for which new candidate polymorphisms now rapidly emerge from genome wide association studies. In the Leiden Longevity Study (n=2415), the offspring of long lived siblings ("offspring") who are genetically enriched for longevity were shown to have a more beneficial metabolic profile compared to their environmentally matched partners ("controls"), including better glucose tolerance. We tested whether the "offspring" carry a lower burden of diabetes risk alleles. Fifteen polymorphisms derived from genome wide association (GWA) scans in type 2 diabetes were tested for association with parameters of glucose metabolism in offspring and controls, and burden of risk alleles was compared between offspring and controls. Among all participants, a higher number of type 2 diabetes risk alleles associated with a higher prevalence of diabetes (P=0.011) and higher serum concentration of glucose (P<0.016) but not insulin (P=0.450). None of the polymorphisms differed in frequency between the offspring and controls (all P>0.05), nor did the mean total number of risk alleles (P=0.977). The association between polymorphisms and glucose levels did not differ between controls and offspring (Pinteraction=0.523). The better glucose tolerance of the "offspring" is not explained by a lower burden of type 2 diabetes risk alleles, suggesting that specific mechanisms determining longevity exist.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21191145 PMCID: PMC3047139 DOI: 10.18632/aging.100250
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Baseline characteristics of the study groups from the Leiden Longevity Study
| Offspring (n = 1671) | Controls (n = 744) | P-Value | |
| Age in years, mean (SD) | 59.4 (6.5) | 58.7 (7.5) | 0.032 |
| Females, number (%) | 900 (54%) | 429 (58%) | 0.083 |
| Height (cm), mean (95% CI) | 172.9 (172.5–173.2) | 172.9 (172.3–173.4) | 0.951 |
| Weight (kg), mean (95% CI) | 76.1 (75.4–76.8) | 76.8 (75.8–77.8) | 0.279 |
| Body mass index (kg/m2), mean (95% CI) | 25.4 (25.2–25.6) | 25.6 (25.3–25.9) | 0.268 |
| Diabetes Mellitus, number (%) | 60 (4%) | 47 (7%) | 0.003 |
| Hypertension, number (%) | 319 (23%) | 179 (28%) | 0.003 |
| Myocardial infarction, number (%) | 33 (2%) | 25 (4%) | 0.040 |
| Stroke, number (%) | 46 (3%) | 18 (3%) | 0.602 |
| Glucose (mmol/L), mean (95% CI) | 5.75 (5.70–5.81) | 6.01 (5.92–6.09) | <0.001 |
| Insulin (mU/L), geometric mean (95% CI) | 16.1 (15.5–16.8) | 18.0 (16.9–19.1) | 0.006 |
Association of the number of risk alleles associated with type 2 diabetes in offspring and partners combined
| Stratum of number of risk alleles | P for trend | |||
| 5-13 (n=731) | 14-15 (n=647) | 16-23 (n=712) | ||
| Age in years, mean (SD) | 59.2 (6.7) | 59.1 (6.8) | 59.6 (7.0) | 0.541 |
| Females, number (%) | 397 (54%) | 359 (56%) | 393 (55%) | 0.981 |
| Height (m), mean (95% CI) | 172.6 (172.1-173.1) | 173.1 (172.6-173.7) | 173.0 (172.4-173.5) | 0.354 |
| Weight (kg), mean (95% CI) | 76.0 (75.0-77.0) | 76.5 (75.5-77.5) | 76.3 (75.3-77.3) | 0.446 |
| Body mass index (kg/m2), mean (95% CI) | 25.5 (25.2-25.8) | 25.5 (25.2-25.8) | 25.4 (25.1-25.7) | 0.859 |
| Diabetes Mellitus, number (%) | 24 (3%) | 28 (4%) | 39 (6%) | 0.011 |
| Hypertension, number (%) | 140 (19%) | 124 (21%) | 153 (22%) | 0.188 |
| Myocardial infarction, number (%) | 21 (3%) | 12 (2%) | 19 (3%) | 0.133 |
| Stroke, number (%) | 20 (3%) | 16 (3%) | 19 (3%) | 0.194 |
| Glucose (mmol/L), mean (95% CI) | 5.78 (5.70-5.87) | 5.79 (5.69-5.88) | 5.90 (5.82-5.99) | 0.016 |
| Insulin (mU/L), geometric mean (95% CI) | 16.9 (16.0-18.0) | 16.6 (15.5-17.6) | 16.3 (15.3-17.5) | 0.450 |
P-values were calculated with the number of risk alleles as continuous variable, adjusting for age and sex, and using robust standard errors to account for family relationships among the offspring.
Comparison of allele frequencies and number of risk alleles associated with type 2 diabetes in offspring and controls
| Offspring (n = 1671) | Controls (n = 744) | P-Value | |
| Rs10497721 | 0.09 | 0.10 | 0.918 |
| Rs1801282 | 0.87 | 0.88 | 0.363 |
| Rs4402960 | 0.29 | 0.31 | 0.355 |
| Rs10010131 | 0.56 | 0.59 | 0.152 |
| Rs7754840 | 0.33 | 0.32 | 0.559 |
| Rs13266634 | 0.70 | 0.69 | 0.594 |
| Rs564398 | 0.57 | 0.57 | 0.970 |
| Rs10811661 | 0.83 | 0.82 | 0.473 |
| Rs1111875 | 0.60 | 0.59 | 0.280 |
| Rs7903146 | 0.27 | 0.27 | 0.816 |
| Rs5219 | 0.35 | 0.37 | 0.409 |
| Rs1495377 | 0.50 | 0.50 | 0.754 |
| Rs8050136 | 0.38 | 0.37 | 0.771 |
| Rs4430796 | 0.49 | 0.48 | 0.399 |
| Rs757210 | 0.39 | 0.38 | 0.357 |
| Mean number of risk alleles | 14.5 | 14.5 | 0.977 |
| (95% CI) | (14.4-14.6) | (14.3-14.7) |
Allele frequencies are reported for the T2D risk alleles. P-values report difference in genotype trend between offspring and partners and account for family relations among the offspring by using robust standard errors.
Figure 1.Association between increasing number of type 2 diabetes susceptibility loci, partitioned according to tertiles, and area under the curve for glucose. T2D: type 2 diabetes. Results were adjusted for sex and age. Number of participants per tertile for group of offspring: first tertile (n = 44), second tertile (n = 38), third tertile (n = 29). Number of participants per tertile for group of controls: first tertile (n = 33), second tertile (n = 38), third tertile (n = 34).
Information of the fifteen selected SNPs associated with type 2 diabetes in Genome Wide Association studies
| SNP | Gene/locus | Location | Risk allele | References |
| Rs10497721 | 2q32.3 | A/ | [ | |
| Rs1801282 | 3p25 | [ | ||
| Rs4402960 | 3q27.2 | T/ | [ | |
| Rs10010131 | 4q16 | [ | ||
| Rs7754840 | 6p22.3 | C/ | [ | |
| Rs13266634 | 8q24.11 | [ | ||
| Rs564398 | 9q21 | [ | ||
| Rs10811661 | 9q21 | [ | ||
| Rs1111875 | 10q23 | [ | ||
| Rs7903146 | 10q25.2 | T/ | [ | |
| Rs5219 | 11p15.1 | T/ | [ | |
| Rs1495377 | 12q21.1 | T2D | [ | |
| Rs8050136 | 16q12.2 | A/ | [ | |
| rs4430796 | 17q12 | [ | ||
| rs757210 | 17q12 | T/ | [ |
Abbreviations: TMEFF2, transmembrane protein with EGF-like and 2 follistatin like domains 2; PPARG, peroxisome proliferator activated receptor γ; IGFBP2, IGF binding protein 2; WFS1, Wolfram Syndrome 1; CDKAL1, CDK5 reg. sub. Ass. protein 1; SLC30A8, solute carries family 30; CDKN2A/2B, cyclin-dependent kinase inhibitor 2A/2B; HHEX, Hematopoietically expressed Homeobox; TCF7L2, transcription factor 7 like 2; KCNJ11, Potassium channel inwardly rectifying submfamily J member 11; TSPAN8, tatraspanin8; FTO, fat mass and obesity associated; HNF1B, HNF1 homeobox B